Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;29(8):1245-51.
doi: 10.1007/s00381-013-2087-7. Epub 2013 Apr 28.

Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT/RT)

Affiliations

Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT/RT)

Kyu-Won Shim et al. Childs Nerv Syst. 2013 Aug.

Abstract

Objective: This study investigated epigenetic modifications in human central nervous system atypical teratoid rhabdoid tumors (AT/RTs), in response to inhibition of insulin-like growth factor receptor 1 (IGF-1R).

Materials and methods: Tumor tissue was obtained from two pediatric patients, tissue was dissociated, and primary cultures were established. Cultured cells were treated with picropodophyllin (PPP; 0, 1, and 2 μM for 48 h), a selective IGF-1R inhibitor. Histone acetylation and methylation patterns (H3K9ac, H3K18ac, H3K4me3, H3K27me3) and levels of histone deacetylases (HDACs; HDAC1, HDAC3, and SirT1) and histone acetyl transferases (GCN5 and p300) were examined. H3K9ac and H3K18ac decreased in response to treatment with PPP. HDAC levels showed a biphasic response, increasing with 1 μM PPP, but then decreasing with 2 μM PPP.

Conclusion: Inhibition of IGF-1R modified epigenetic status in AT/RT. Determining the mechanisms behind these modifications will guide the development of novel therapeutic targets for this malignant embryonal cancer.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Oncol. 2005 Mar 1;23(7):1491-9 - PubMed
    1. J Clin Oncol. 2009 Jan 20;27(3):385-9 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 - PubMed
    1. Cell Stem Cell. 2009 Jun 5;4(6):568-80 - PubMed
    1. Nat Genet. 2002 Mar;30(3):329-34 - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources